Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients
- 93 Downloads
Valganciclovir (VGCV) treatment is recommended for the prevention of cytomegalovirus (CMV) infection in renal allograft recipients. The aim of the present study is to investigate the pharmacokinetic characteristics of ganciclovir (GCV) after administration of VGCV in Chinese adult renal allograft recipients and estimate the exposure to GCV using limited sampling strategy (LSS).
Forty Chinese renal allograft recipients were given 450 mg or 900 mg VGCV daily. Blood samples were drawn before treatment and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h after 5 days of VGCV therapy, and the plasma concentrations of VGCV and GCV were determined using a liquid chromatography-mass spectrometry assay. The major pharmacokinetic parameters for GCV and VGCV were determined using a noncompartmental assay. Multiple stepwise linear regression analysis was conducted to establish a model equation for the estimation of the GCV AUC0–24 h in Chinese patients using LSS.
In the 450 and 900 mg groups, the Cmax for VGCV was 0.2 ± 0.10 and 0.4 ± 0.16 mg/L, respectively; the Cmax for GCV was 4.2 ± 1.1 and 8.6 ± 1.6 mg/L, respectively; and the AUC0–24 h for GCV was 28.4 ± 8.4 and 60.7 ± 17.5 mg·h/L, respectively. For the establishment of LSS models, 40 patients were divided into the training group (n = 24) and validation group (n = 16). The model equations used for the calculation of AUC0–24 h for GCV were established in the training group by using multiple linear regression assay. Equations including AUC = 8.1 + 29.7 × C0 + 5.7 × C4 (r2 = 0.91) and AUC = − 0.4 + 11.0 × C0 + 2.1 × C2 + 13.7 × C8 (r2 = 0.98) were acceptable. The %MPE and %MAPE values obtained from the validation group for the two model equations were 5.89 ± 14.5% and 12.1 ± 9.53%, and − 1.30 ± 4.40% and 3.28 ± 3.11%, respectively.
The LSS models that included C0 and C4 or C0, C2, and C8 in the estimation of AUC0–24 h for GCV had favorable performance and can be used for therapeutic drug monitoring in the prevention of CMV infection using VGCV in Chinese renal allograft recipients.
KeywordsRenal transplantation Valganciclovir (VGCV) Ganciclovir (GCV) Pharmacokinetics Limited sampling strategy Therapeutic drug monitoring
This work was supported by the National Natural Science Foundation of China (Grant Number: 81473275) and Medical and Technology Intercrossing Research Foundation of Shanghai Jiao Tong University (Grant Number: YG2016MS60).
Compliance with ethical standards
The research was conducted in accordance with the ethical standards of the Helsinki Declaration. This study protocol was approved by the Ethics Committee of Rui-Jin Hospital, which is affiliated with the Shanghai Jiao-Tong University School of Medicine, and informed consent was obtained from each patient prior to the study.
Conflict of interest
The authors declare that they have no conflict of interest.
- 11.Kotton CN, Kumar D, Caliendo AM, Åsberg A, Chou S, Danziger-Isakov L, Humar A (2013) Transplantation society international CMV consensus group: updated internationalconsensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96:333–360CrossRefGoogle Scholar
- 15.Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, Abramowicz D, Jardine AG, Voulgari AT, Ives J, Hauser IA, Peeters P (2010) The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 10(5):1228–1237CrossRefGoogle Scholar
- 16.Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, Abramowicz D, Ives JAL, Farhan M, Peeters P (2010) Extended valganciclovir prophylaxis in D+/R-kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease:two-year results of the IMPACT study. Transplantation 90(12):1427–1431CrossRefGoogle Scholar
- 23.Wiltshire H, Hirankarn S, Farrell C, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N (2005) The valganciclovir solid organ transplant study group. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organtransplant recipients. Clin Pharmacokinet 44:495–507CrossRefGoogle Scholar
- 27.Mcgavin JK, Goa KL (1998) Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 56(1):1153–1183Google Scholar
- 30.Rondeau E, Farquet C, Fries D et al (1991) Treatment of cytomegalovirus infections with ganciclovir in kidney transplant recipients. Clinical and pharmacokinetic study. Presse Méd 20(40):2030–2032Google Scholar
- 31.Wolfe EJ, Mathur V, Tomlanovich S et al (1997) Pharmacokinetics of mycophenolatemofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. Pharmacotherapy 17:591–598Google Scholar
- 34.Mahmood I, Miller R (1999) Comparison of the Bayesian approach and a limited sampling model for the estimation of AUC and Cmax: a computer simulation analysis. Int J Clin Pharmacol Ther 37:439–445Google Scholar